Edcon Chang

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 62(Granted Patents)

Company Filing History:

9 out of 1,179

Takeda Pharmaceutical Company Limited

Takeda San Diego, Inc.

Years Active: 2010-2016

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9403819 - Apoptosis signal-regulating kinase 1 inhibitors (2016-08-02),

2. 9371321 - Azaindole derivatives (2016-06-21),

3. 9045496 - N-substituted oxazinopteridines and oxazinopteridinones (2015-06-02),

4. 8921358 - Apoptosis signal-regulating kinase 1 inhibitors (2014-12-30),

5. 8835420 - Azaindole derivatives (2014-09-16),

6. 8802695 - Apoptosis signal-regulating kinase 1 inhibitors (2014-08-12),

7. 8791107 - N-substituted oxazinopteridines and oxazinopteridinones (2014-07-29),

8. 8580838 - 5-membered heterocycle-based p38 kinase inhibitors (2013-11-12),

9. 8461163 - Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 (2013-06-11),

10. 8410160 - 5-membered heterocycle-based P38 kinase inhibitors (2013-04-02),

11. 8242117 - 5-membered heterocycle-based p38 kinase inhibitors (2012-08-14),

12. 8178555 - Apoptosis signal-regulating kinase 1 inhibitors (2012-05-15),

13. 7981904 - Acetyl CoA carboxylase inhibitors (2011-07-19),

14. 7863314 - 5-membered heterocycle-based p38 kinase inhibitors (2011-01-04),

15. 7759339 - Hydroxysteroid dehydrogenase inhibitors (2010-07-20),

Title: **Edcon Chang: Innovator in Pharmaceutical Patents**

Introduction

Edcon Chang, an innovative inventor based in San Diego, California, has made significant contributions to the field of pharmaceuticals with a total of 15 patents to his name. His work focuses on developing compounds that target various diseases, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest patents are significant inventions relating to apoptosis signal-regulating kinase 1 inhibitors. This invention encompasses compounds that inhibit ASK1, along with pharmaceutical compositions, kits, and methods for utilizing these compounds. Additionally, he has developed azaindole derivatives, which are compounds aimed at treating immunological disorders, cardiovascular disease, cancer, and other conditions related to PI3Kδ.

Career Highlights

Edcon has worked in leading pharmaceutical companies such as Takeda Pharmaceutical Company Limited and Novartis AG, where he has honed his skills and expertise in drug development and innovation. His experience in these organizations has been instrumental in his successful patent registrations.

Collaborations

Throughout his career, Edcon has collaborated with notable colleagues, including Angie Vassar and Olga M Fryszman. These partnerships have contributed to the development of innovative solutions in the medicinal field and reflect the collaborative spirit of scientific research.

Conclusion

Edcon Chang's contributions to the pharmaceutical industry illustrate an impactful career dedicated to improving health outcomes through innovation. His extensive patent portfolio highlights his inventive capabilities and commitment to pushing the boundaries of medical science.

This text is generated by artificial intelligence and may not be accurate.